Table 1.
Characteristics of study participants treated with breast-conserving surgery and adjuvant radiotherapy between October 2013 and October 2016, with at least 12 months' follow-up (n = 836)
| Characteristic | No. of patients (%) |
|---|---|
| Age at inclusion, median (IQR), y | 58 (16) |
| Neo-adjuvant systemic treatment | |
| None | 699 (83) |
| Chemotherapy | 49 (6) |
| Chemotherapy and immunotherapy | 88 (11) |
| Oncoplastic surgery | |
| Yes | 92 (11) |
| No | 396 (47) |
| Unknown | 348 (42) |
| Sentinel node biopsy | |
| Yes | 705 (84) |
| No | 131 (16) |
| Axillary lymph node dissection | |
| Yes | 120 (14) |
| No | 716 (86) |
| Pathological tumor stage | |
| Ductal carcinoma in situ | 102 (12) |
| T1 | 594 (71) |
| T2 | 133 (16) |
| ≥T3 | 7 (1) |
| Radiotherapy treatment | |
| Local radiotherapy | 656 (78) |
| Locoregional radiotherapy* | 180 (22) |
| Local radiotherapy boost (ie, tumor bed) | |
| Yes | 286 (34) |
| No | 459 (55) |
| Unknown | 91 (11) |
| Adjuvant chemotherapy | |
| Yes | 232 (28) |
| No | 604 (72) |
| Adjuvant endocrine therapy | |
| Yes | 656 (79) |
| No | 180 (21) |
*
Includes radiotherapy on axillary and/or periclavicular lymph nodes. IQR = interquartile range.